86 related articles for article (PubMed ID: 15931264)
1. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
3. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
[TBL] [Abstract][Full Text] [Related]
4. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
5. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1.
Ashman LK; Bühring HJ; Aylett GW; Broudy VC; Müller C
J Cell Physiol; 1994 Mar; 158(3):545-54. PubMed ID: 7510297
[TBL] [Abstract][Full Text] [Related]
7. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
[TBL] [Abstract][Full Text] [Related]
8. Expression of the flt3 receptor and its ligand on hematopoietic cells.
Brasel K; Escobar S; Anderberg R; de Vries P; Gruss HJ; Lyman SD
Leukemia; 1995 Jul; 9(7):1212-8. PubMed ID: 7630197
[TBL] [Abstract][Full Text] [Related]
9. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
10. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.
Dehmel U; Zaborski M; Meierhoff G; Rosnet O; Birnbaum D; Ludwig WD; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):261-70. PubMed ID: 8637235
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
13. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
14. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts.
Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W
Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893
[TBL] [Abstract][Full Text] [Related]
15. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
16. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
17. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
18. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
19. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.
Meierhoff G; Dehmel U; Gruss HJ; Rosnet O; Birnbaum D; Quentmeier H; Dirks W; Drexler HG
Leukemia; 1995 Aug; 9(8):1368-72. PubMed ID: 7643626
[TBL] [Abstract][Full Text] [Related]
20. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
